Brilliant Violet 421™ anti-human CD16

Antibodies Single
Sony
3G8
Flow Cytometry
Mouse IgG1, κ
Human
Human PMN cells
2110190
$443.00

Description

CD16 is known as low affinity IgG receptor III (FcγRIII). It is expressed as two distinct forms (CD16a and CD16b). CD16a (FcγRIIIA) is a 50-65 kD polypeptide-anchored transmembrane protein. It is expressed on the surface of NK cells, activated monocytes, macrophages, and placental trophoblasts in humans. CD16b (FcγRIIIB) is a 48 kD glycosylphosphatidylinositol (GPI)-anchored protein. Its extracellular domain is over 95% homologous to that of CD16a, and it is expressed specifically on neutrophils. CD16 binds aggregated IgG or IgG-antigen complex which functions in NK cell activation, phagocytosis, and antibody-dependent cell-mediated cytotoxicity (ADCC).

Formulation

Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).

Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤5 microL per million cells or 5 microL per 100 microL of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.

Brilliant Violet 421™ excites at 405 nm and emits at 421 nm. The standard bandpass filter 450/50 nm is recommended for detection. Brilliant Violet 421™ is a trademark of Sirigen Group Ltd.

This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.

References

1. Knapp W, et al. Eds. 1989. Leucocyte Typing IV. Oxford University Press. New York.
2. Schlossman S, et al. Eds. 1995. Leucocyte Typing V. Oxford University Press. New York.
3. Edberg J, et al. 1997. J. Immunol. 159:3849. (IP)
4. Hoshino S, et al. 1991. Blood 78:3232. (Stim)
5. Tamm A, et al. 1996. Immunol. 157:1576. (Block)
6. Da Silva DM, et al. 2001. Int. Immunol. 13:633. (IHC)
7. Holl V, et al. 2004. J. Immunol. 173:6274. (Block)
8. Hober D, et al. 2002. J. Gen. Virol. 83:2169. (Block)
9. Brainard DM, et al. 2009. J. Virol. 83:7305. PubMed
10. Smed-Sörensen A, et al. 2008. Blood 111:5037. (Block) PubMed
11. Timmerman KL, et al. 2008. J. Leukoc. Biol. 84:1271. (FC) PubMed
12. Yoshino N, et al. 2000. Exp. Anim. (Tokyo) 49:97. (FC)
13. Rout N, et al. 2010. PLoS One 5:e9787. (FC)
14. Kim WK, et al. 2006. Am. J. Pathol. 168:822. (FC)
15. Boltz A, et al. 2011. J. Biol Chem. 286:21896. PubMed
16. Wu Z, et al. 2013. J. Virol. 87:7717. PubMed